NeurologyLive® Friday 5 — February 13, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more buttons for more details and information about each highlight.

1: Rethinking Multiple Sclerosis Clinical Course Classifications in the Modern Era: Daniel Ontaneda, MD, PhD

At ACTRIMS Forum 2026, Daniel Ontaneda, MD, PhD, a staff neuroimmunologist at Cleveland Clinic, discussed how evolving imaging and biological insights have reshaped the way clinicians define and talk about multiple sclerosis. [WATCH TIME: 3 minutes]

2: Inside the Push for Myelin Repair: Riley Bove, MD

At ACTRIMS Forum 2026, Riley Bove, MD, associate professor of neurology at the University of California, San Francisco discussed the evolving approach to remyelination in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

3: Uncovering Reasons Behind Disease-Modifying Therapy Delays in Underserved MS Populations: Marisa McGinley, DO

At ACTRIMS Forum 2026, Marisa McGinley, DO, staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis, provided background on a study focused on patient-reported barriers to timely multiple sclerosis treatment initiation. [WATCH TIME: 4 minutes]

4: NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis

In our latest NeuroVoices Q&A, Katrina Bawden, MSN, MSCN, FNP-C, a nurse practitioner at the Rocky Mountain MS Clinic, discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

5: Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care

At ACTRIMS Forum 2026, neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discussed the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

Click here to view our latest video interview shorts with neurology experts.